Pure Autonomic Failure (PAF): Symptoms, Diagnosis, and Prognosis

Pure autonomic failure (PAF) is a rare neurodegenerative disease characterized by severe, progressive autonomic dysfunction — particularly orthostatic hypotension — without the motor features (parkinsonism or cerebellar ataxia) that define multiple system atrophy. It is one of the most severe forms of dysautonomia and, like MSA, is caused by the abnormal accumulation of alpha-synuclein, placing it in the family of diseases called synucleinopathies alongside Parkinson's disease, MSA, and Lewy body dementia.

What Is PAF?

PAF was first described by Bradbury and Eggleston in 1925 as "idiopathic orthostatic hypotension" — a condition of severe blood pressure instability without identifiable cause. The defining features are:

• Severe neurogenic orthostatic hypotension: Blood pressure drops dramatically upon standing (typically >30 mmHg systolic), causing lightheadedness, pre-syncope, and syncope
• Absence of motor features: No parkinsonism, no cerebellar ataxia, no dementia
• Widespread autonomic failure: Affecting not only blood pressure regulation but also heart rate, sweating, bladder function, and gastrointestinal motility
• Peripheral nervous system predominance: Unlike MSA, which involves primarily central nervous system degeneration, PAF involves degeneration of peripheral autonomic neurons

PAF is significantly rarer than MSA, with a prevalence estimated at 1–2 per 100,000. It typically presents in the sixth to seventh decade of life and affects men slightly more than women.

The Alpha-Synuclein Connection

Like MSA and Parkinson's disease, PAF is caused by the abnormal aggregation of alpha-synuclein protein. In PAF, alpha-synuclein accumulates primarily in peripheral autonomic neurons — the neurons of the sympathetic ganglia and the autonomic nerve fibers that innervate blood vessels, the heart, the bladder, and the gastrointestinal tract. This peripheral deposition distinguishes PAF from MSA (where alpha-synuclein accumulates centrally in glial cells) and from Parkinson's disease (where it accumulates in central dopaminergic neurons, though peripheral involvement also occurs).

This distinction has important implications for prognosis. Because PAF involves primarily peripheral neurodegeneration, it progresses more slowly than MSA and does not (initially) affect the brain regions responsible for movement, cognition, or coordination.

Symptoms

The symptoms of PAF reflect the widespread failure of the peripheral autonomic nervous system:

Orthostatic hypotension is the dominant and most disabling symptom. Blood pressure drops dramatically upon standing, causing severe lightheadedness, visual disturbances, weakness, and syncope. The drop is often much larger than in POTS or vasovagal syncope — falls of 40–60 mmHg or more are common. Unlike POTS, the heart rate does not rise appropriately because the same autonomic damage that prevents vasoconstriction also impairs the cardiac acceleration response.

Supine hypertension is a paradoxical feature of PAF that complicates management. When lying flat, blood pressure rises significantly (often to 160–180 mmHg or higher) because the same autonomic dysfunction that prevents vasoconstriction when standing also prevents the normal nocturnal blood pressure dip. This creates a difficult management challenge: treating orthostatic hypotension (which requires raising blood pressure) can worsen supine hypertension, and vice versa.

Urinary dysfunction is common, including urgency, frequency, incomplete emptying, and urinary retention. In men, erectile dysfunction is often an early symptom.

Gastrointestinal dysfunction includes constipation (often severe), gastroparesis, and dysphagia.

Anhidrosis (reduced or absent sweating) is common and can cause heat intolerance and difficulty regulating body temperature.

How PAF Differs from MSA and Parkinson's Disease

The conversion risk deserves emphasis: approximately 30–34% of patients initially diagnosed with PAF eventually develop motor features consistent with MSA or Parkinson's disease, sometimes years after the autonomic symptoms began. Regular neurological follow-up is essential for PAF patients to monitor for emerging motor features.

Diagnosis

PAF is diagnosed clinically based on the combination of severe neurogenic orthostatic hypotension and the absence of motor features. Several tests support the diagnosis:

Plasma norepinephrine levels: In PAF, plasma norepinephrine is very low when measured supine (reflecting peripheral sympathetic denervation) and fails to rise appropriately upon standing. This distinguishes PAF from central causes of autonomic failure (like MSA) where supine norepinephrine may be normal.

Cardiac MIBG scintigraphy: MIBG (metaiodobenzylguanidine) is taken up by sympathetic nerve terminals in the heart. In PAF and Parkinson's disease, cardiac MIBG uptake is markedly reduced, reflecting peripheral sympathetic denervation. In MSA, cardiac MIBG is usually normal or only mildly reduced. This test can help distinguish PAF from MSA.

Autonomic function testing: Comprehensive autonomic testing (including tilt table test, QSART, thermoregulatory sweat test, and Valsalva maneuver) demonstrates widespread autonomic failure.

Brain MRI: Usually normal in PAF, helping to exclude MSA (which shows characteristic MRI findings) and other central causes of autonomic failure.

Management

Like MSA, PAF has no disease-modifying treatment. Management focuses on symptom control, particularly orthostatic hypotension.

Non-pharmacological measures: Head-of-bed elevation (10–20 degrees) reduces supine hypertension and improves morning orthostatic tolerance. High salt and fluid intake, compression garments (abdominal binders and thigh-high stockings), and physical counter-maneuvers (leg crossing, squatting) are all helpful.

Pharmacological treatment of orthostatic hypotension: Fludrocortisone (volume expansion), midodrine (vasoconstrictor), and droxidopa (norepinephrine precursor) are the primary medications. Droxidopa is particularly relevant in PAF because the peripheral sympathetic denervation means that the body cannot synthesize adequate norepinephrine — droxidopa provides a direct precursor.

Managing supine hypertension: Short-acting antihypertensives taken at bedtime (such as nitroglycerin patches or captopril) can reduce nocturnal blood pressure without worsening daytime orthostatic hypotension. Patients should sleep with the head of the bed elevated and avoid lying flat during the day.

Prognosis: PAF progresses more slowly than MSA, and many patients maintain a reasonable quality of life for years to decades with appropriate management. The primary risks are falls and injury from syncope, and the complications of supine hypertension (stroke, cardiac disease). Regular monitoring for conversion to MSA or Parkinson's disease is essential.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your treatment plan.